The High-Affinity Binding Site for Tricyclic Antidepressants Resides in the Outer Vestibule of the Serotonin Transporter
Open Access
- 9 September 2010
- journal article
- research article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Molecular Pharmacology
- Vol. 78 (6), 1026-1035
- https://doi.org/10.1124/mol.110.067538
Abstract
The structure of the bacterial leucine transporter from Aquifex aeolicus (LeuTAa) has been used as a model for mammalian Na+/Cl−-dependent transporters, in particular the serotonin transporter (SERT). The crystal structure of LeuTAa liganded to tricyclic antidepressants predicts simultaneous binding of inhibitor and substrate. This is incompatible with the mutually competitive inhibition of substrates and inhibitors of SERT. We explored the binding modes of tricyclic antidepressants by homology modeling and docking studies. Two approaches were used subsequently to differentiate between three clusters of potential docking poses: 1) a diagnostic SERTY95F mutation, which greatly reduced the affinity for [3H]imipramine but did not affect substrate binding; 2) competition binding experiments in the presence and absence of carbamazepine (i.e., a tricyclic imipramine analog with a short side chain that competes with [3H]imipramine binding to SERT). Binding of releasers (para-chloroamphetamine, methylene-dioxy-methamphetamine/ecstasy) and of carbamazepine were mutually exclusive, but Dixon plots generated in the presence of carbamazepine yielded intersecting lines for serotonin, MPP+, paroxetine, and ibogaine. These observations are consistent with a model, in which 1) the tricyclic ring is docked into the outer vestibule and the dimethyl-aminopropyl side chain points to the substrate binding site; 2) binding of amphetamines creates a structural change in the inner and outer vestibule that precludes docking of the tricyclic ring; 3) simultaneous binding of ibogaine (which binds to the inward-facing conformation) and of carbamazepine is indicative of a second binding site in the inner vestibule, consistent with the pseudosymmetric fold of monoamine transporters. This may be the second low-affinity binding site for antidepressants.This publication has 40 references indexed in Scilit:
- Transmembrane Domain 6 of the Human Serotonin Transporter Contributes to an Aqueously Accessible Binding Pocket for Serotonin and the Psychostimulant 3,4-Methylene Dioxymethamphetamine*Online Journal of Public Health Informatics, 2010
- The N Terminus of Monoamine Transporters Is a Lever Required for the Action of Amphetamines*Online Journal of Public Health Informatics, 2010
- Mutational Mapping and Modeling of the Binding Site for (S)-Citalopram in the Human Serotonin TransporterOnline Journal of Public Health Informatics, 2010
- Antidepressant specificity of serotonin transporter suggested by three LeuT–SSRI structuresNature Structural & Molecular Biology, 2009
- Location of the Antidepressant Binding Site in the Serotonin TransporterOnline Journal of Public Health Informatics, 2009
- Mechanism for alternating access in neurotransmitter transportersProceedings of the National Academy of Sciences of the United States of America, 2008
- The binding sites for cocaine and dopamine in the dopamine transporter overlapNature Neuroscience, 2008
- The Mechanism of a Neurotransmitter:Sodium Symporter—Inward Release of Na+ and Substrate Is Triggered by Substrate in a Second Binding SiteMolecular Cell, 2008
- QMEAN: A comprehensive scoring function for model quality assessmentProteins, 2007
- Identification of a chloride ion binding site in Na + /Cl − -dependent transportersProceedings of the National Academy of Sciences of the United States of America, 2007